10

15

30

## WHAT IS CLAIMED IS:

- 1. A method of treating androgenic alopecia comprising administering to a person in need of such treatment a  $5\alpha$ -reductase 2 inhibitor in a dosage amount under 5.0 mgs/day.
  - $2. \qquad \text{The method of Claim 1 wherein the dosage amount is from about 0.01 to 3.0 mgs/day.}$
- 3. The method of Claim 1 wherein the dosage amount is from about 0.05 to 1.0 mg/day.
- 4. The method of Claim 1 wherein the dosage amount is about  $0.05 \ mg/day$ .
  - 5. The method of Claim 1 wherein the dosage amount is about 0.2 mgs/day.
- 20 6. The method of Claim 1 wherein the androgenic alopecia is male pattern baldness.
  - 7. The method of Claim 1 wherein the  $5\alpha$ -reductase 2 inhibitor is administered orally.
- 25 8. The method of Claim 1 wherein the 5α-reductase 2 inhibitor is administered topically.
  - 9. The method of Claim 1 wherein the  $5\alpha$ -reductase 2 inhibitor has the structural formula I

10

15

20

25

30

or a pharmaceutically acceptable salt thereof wherein:

R1 is hydrogen, methyl or ethyl;

R2 is a hydrocarbon radical selected from straight and branched chain alkyl of from 1-12 carbons or monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halogen (Cl, F or Br) substituents;

R' is hydrogen or methyl;

 $R^{\prime\prime}$  is hydrogen or  $\beta\text{-methyl};$  and  $^{\prime\prime}$ 

R''' is hydrogen,  $\alpha$ -methyl or  $\beta$ -methyl.

10. The method of Claim 1 wherein the  $5\alpha\text{-reductase}\ 2$  inhibitor has the structural formula II

or a pharmaceutically acceptable salt thereof wherein  $R^{\mbox{\scriptsize $1$}}$  is hydrogen, or methyl; and

R3 is branched chain alkyl of from 4-8 carbons.

15

25

- 11. A method of treating androgenic alopecia comprising administering to a person in need of such treatment  $17\beta$ -(N-tert-butylcarbamoyl)-4-aza- $5\alpha$ -androst-1-ene-3-one in a dosage amount under 5.0 mgs/day.
- 12. The method of Claim 11 wherein the androgenic alopecia is male pattern baldness.
- 13. The method of Claim 11 wherein the dosage amount is from about 0.01 to 3.0 mgs/day.
- The method of Claim 11 wherein the dosage amount is from about 0.05 to 1.0 mg/day.
  - 15. The method of Claim 11 wherein the dosage amount is about 0.05 mg/day.
- $^{20}$   $\,$  is about 0.2 mg/day.
  - 17. The method of Claim 11 wherein the  $17\beta\text{-}(N\text{-}tert\text{-}butylcarbamoyl})\text{-}4\text{-}aza\text{-}5\alpha\text{-}androst\text{-}1\text{-}ene\text{-}3\text{-}one$  is administered topically.
  - 18. The method of Claim 11 wherein the  $17\beta$ -(N-tert-butylcarbamoyl)-4-aza- $5\alpha$ -androst-1-ene-3-one is administered orally.
- $^{30}$   $\,$  19. The method of Claim 18 wherein the dosage amount is about 0.2 mg/day.
  - $20. \;\;$  The method of Claim 18 wherein the dosage amount it about 0.05 mg/day.

- 21. A method of arresting and reversing androgenic alopecia comprising administering to a person in need of such treatment a  $5\alpha$ -reductase 2 inhibitor in a dosage amount under 5.0 mgs/day.
- 22. A method of lowering the level of  $5\alpha$ -dihydrotestosterone in human scalp comprising administering to a person in need of such treatment a  $5\alpha$ -reductase 2 inhibitor in a dosage amount under 5.0 mgs/day.
- 23. The method of Claim 22 wherein the dosage amount is from about 0.01 to 3.0 mgs/day.
- 24. The method of Claim 22 wherein the dosage amount is from about 0.05 to 1.0 mg/day.
  - 25. The method of Claim 22 wherein the dosage amount is about 0.05 mg/day.
- 26. The method of Claim 22 wherein the dosage amount is about 0.2 mg/day.
  - $\,$  27. The method of Claim 22 wherein the dosage amount is about 1.0 mg/day.

5

10